arrow
C

Cheng-Ta Yang

chang gung memorial hospital
H指数:52
被引数:9,983

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis

临床特征和接受达可替尼45或30 mg起始剂量治疗的晚期EGFR突变非小细胞肺癌的结局:一项回顾性多中心分析

2026-06-250
PRE
Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study

更正:顺次使用阿法替尼和奥希替尼与阿法替尼联合化疗在EGFR突变非小细胞肺癌中的真实世界疗效比较:台湾多中心巨人研究

2026-04-300
OAAI
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer

MAGELLAN方案B1和B3臂:在治疗初治转移性非小细胞肺癌患者中,比较度伐利尤单抗联合化疗与联合化疗并联合奥雷oclumab的疗效。

2025-11-070
PRE
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase 2 trial

Savolitinib 联合 Osimertinib 治疗表皮生长因子突变、MET 扩增的晚期非小细胞肺癌:一项随机 II 期临床试验

2025-10-220
PRE
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

增强型与标准皮肤管理联合阿曼曲妥珠单抗-拉泽替尼在EGFR突变型晚期NSCLC中的应用比较:COCOON全球随机对照试验

2025-09-090
OAAI
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real–world study

不可切除的III期EGFR突变非小细胞肺癌患者接受放化疗的突变检测、治疗模式与结局:一项全球真实世界研究的最终分析

2025-09-080
PREAI
Consensus of the Taiwanese dermatological association and Taiwan Lung Cancer Society on the prevention and management of tyrosine kinase inhibitor-related skin toxicities in patients with non-small cell lung cancer: An updated version incorporating Taiwanese treatment experience
2025-05-011
OAAI
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial

一线纳武利尤单抗联合铂类化疗和贝伐珠单抗治疗晚期非鳞非小细胞肺癌:TASUKI-52 III期随机试验3年随访

2025-03-010
PRE
Clinical outcome analysis of different first- and second-generation EGFR-tyrosine kinase inhibitors in untreated patients with EGFR-mutated non-small cell lung cancer with baseline brain metastasis

EGFR突变非小细胞肺癌伴基线脑转移患者中,不同一代和二代EGFR酪氨酸激酶抑制剂的临床疗效分析

2025-02-260
OA
Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity

I类HLA等位基因与奥希替尼诱导的超敏反应风险增加相关

2025-01-010
PRE
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Durvalumab加或不加Tremelimumab联合化疗作为转移性非小细胞肺癌一线治疗的简要报告: POSEIDON 3期研究中肿瘤PD-L1表达的结果

2024-05-013
OAAI
Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
2024-04-050
PRE
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study

在台湾有或没有肺癌家族史的从不吸烟者中进行低剂量CT筛查: 一项前瞻性队列研究

2024-02-0135
PRE